IL75597A - Synergistic mixtures of interferons and tumour necrosis factor - Google Patents

Synergistic mixtures of interferons and tumour necrosis factor

Info

Publication number
IL75597A
IL75597A IL75597A IL7559785A IL75597A IL 75597 A IL75597 A IL 75597A IL 75597 A IL75597 A IL 75597A IL 7559785 A IL7559785 A IL 7559785A IL 75597 A IL75597 A IL 75597A
Authority
IL
Israel
Prior art keywords
necrosis factor
interferons
tumour necrosis
synergistic mixtures
interferon
Prior art date
Application number
IL75597A
Other languages
English (en)
Other versions
IL75597A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL75597A0 publication Critical patent/IL75597A0/xx
Publication of IL75597A publication Critical patent/IL75597A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL75597A 1984-06-23 1985-06-21 Synergistic mixtures of interferons and tumour necrosis factor IL75597A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843423234 DE3423234A1 (de) 1984-06-23 1984-06-23 Synergistische mischungen von interferonen und tumor-nekrose-faktor

Publications (2)

Publication Number Publication Date
IL75597A0 IL75597A0 (en) 1985-10-31
IL75597A true IL75597A (en) 1991-11-21

Family

ID=6238998

Family Applications (1)

Application Number Title Priority Date Filing Date
IL75597A IL75597A (en) 1984-06-23 1985-06-21 Synergistic mixtures of interferons and tumour necrosis factor

Country Status (16)

Country Link
US (1) US4791101A (fr)
EP (1) EP0170843B1 (fr)
JP (1) JPS6115842A (fr)
AT (1) ATE82508T1 (fr)
AU (2) AU593212B2 (fr)
CA (1) CA1258426A (fr)
DD (2) DD250053A5 (fr)
DE (2) DE3423234A1 (fr)
DK (1) DK282585A (fr)
GR (1) GR851492B (fr)
HU (1) HU206270B (fr)
IE (1) IE59289B1 (fr)
IL (1) IL75597A (fr)
NZ (1) NZ212513A (fr)
PH (1) PH24406A (fr)
ZA (1) ZA854682B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
EP0368367A1 (fr) * 1984-12-21 1990-05-16 Biogen, Inc. Purification, production et utilisation de facteurs de nécrose de tumeur
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
CA1291706C (fr) * 1986-04-03 1991-11-05 Alfred Rudolph THERAPIE A BASE D'INTERFERON-.beta. ET D'INTERLEUKINE-2
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (fr) * 1986-04-09 1991-10-08 Cetus Corporation TRAITEMENT A BASE D'INTERLEUKINE-2 ET (OU) D'INTERFERON .beta. ET FACTEUR DE NECROSE TUMORALE
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
PT85076B (pt) * 1986-06-16 1990-07-31 Genentech Inc Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa
US5362490A (en) * 1986-07-25 1994-11-08 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Human myelomonocyte interferon-gamma, and process for preparation and use thereof
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4980160A (en) * 1986-10-16 1990-12-25 Biogen, Inc. Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases
US4963354A (en) * 1987-01-21 1990-10-16 Genentech, Inc. Use of tumor necrosis factor (TNF) as an adjuvant
EP0392300B1 (fr) * 1989-04-11 1992-08-26 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Utilisation d'au moins une cytokine pour l'obtention d'un médicament pour le traitement systémique des lésions prénéoplastiques
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0783891B1 (fr) * 1995-07-25 2006-12-27 Toray Industries, Inc. Interferon-beta contre les maladies osseuses
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
EP1867718B1 (fr) * 1999-12-13 2010-01-20 Bioniche Life Sciences Inc. Oligonucléotides synthétiques utiles du point de vue thérapeutique
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
EP1318834A2 (fr) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions de melanges de proteines therapeutiques et leurs procedes de production
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (fr) * 2002-11-15 2004-06-03 The General Hospital Corporation Methodes de criblage permettant d'identifier des traitements contre une maladie auto-immune
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
WO2005065079A2 (fr) * 2003-11-10 2005-07-21 Angiotech International Ag Implants medicaux et agents inducteurs de fibrose
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz
EP3936137A1 (fr) 2013-02-07 2022-01-12 The General Hospital Corporation Procédés d'expansion ou de déplétion de lymphocytes t régulateurs
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (fr) 2015-09-29 2024-03-06 The General Hospital Corporation Une composition comprenant bcg pour réduire le cholesterol.
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
WO2019147837A2 (fr) 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Protéines de fusion de cytokines
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN114436088A (zh) * 2020-11-02 2022-05-06 奥的斯电梯公司 用于电梯轿厢的安全出口组件及电梯系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764744B2 (ja) * 1981-11-21 1995-07-12 株式会社林原生物化学研究所 標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
IL71954A0 (en) * 1983-06-01 1984-09-30 Genentech Inc Gamma interferon-lymphotoxin synergism
CA1265444A (fr) * 1983-06-27 1990-02-06 Lloyd J. Old Effet du facteur humain de necrose des tumeurs et de l'interferon humain sur des cellules cancereuses humaines et methodes utilisees
DE3421731A1 (de) * 1984-06-12 1985-12-12 Boehringer Ingelheim International GmbH, 6507 Ingelheim Humaner-tumor-nekrose-faktor
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor

Also Published As

Publication number Publication date
US4791101A (en) 1988-12-13
JPS6115842A (ja) 1986-01-23
AU4393185A (en) 1986-01-02
NZ212513A (en) 1988-08-30
DD250053A5 (de) 1987-09-30
EP0170843A1 (fr) 1986-02-12
DE3586833D1 (de) 1992-12-24
IE851547L (en) 1985-12-23
DK282585A (da) 1985-12-24
DK282585D0 (da) 1985-06-21
HUT37891A (en) 1986-03-28
HU206270B (en) 1992-10-28
CA1258426A (fr) 1989-08-15
DD238725A5 (de) 1986-09-03
PH24406A (en) 1990-06-13
IE59289B1 (en) 1994-02-09
AU4416785A (en) 1986-01-02
AU593212B2 (en) 1990-02-08
ATE82508T1 (de) 1992-12-15
EP0170843B1 (fr) 1992-11-19
IL75597A0 (en) 1985-10-31
GR851492B (fr) 1985-11-25
DE3423234A1 (de) 1986-02-06
ZA854682B (en) 1987-02-25

Similar Documents

Publication Publication Date Title
IL75597A (en) Synergistic mixtures of interferons and tumour necrosis factor
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
FI863160A0 (fi) Anlaeggning foer fiskodling i havsvatten.
DE3381553D1 (de) Synergistische humaninterferonaktivitaet.
IT8348746A0 (it) Derivati amminometil-benzenici arilsostituiti ad attivita' regolatrice del ritmo cardiaco e composizioni che li contengono
PT78773A (en) The effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3685484D1 (fr)
DE3479290D1 (en) Synergistic composition comprising gamma interferon and lymphotoxin, and its preparation
IT8347557A0 (it) Polipeptide avente attivita' di interferon, composizione che lo conti ene e procedimento di preparazione
IT8219156A0 (it) Dado meccanico di tipo autobloccabile ed autopulitore.
DE3777224D1 (de) Verwendung von interferon-beta und interleukin-2 in der kombinationstherapie und zusammensetzungen dazu.
FI853307A7 (fi) Ihmisen lymfoblastoidi -leukosyyttihydridi-interferoneja.
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
IT209247Z2 (it) Struttura di scudo da difesa, in particolare del tipo antiproiettili.
IT8523222A0 (it) Struttura legnosa multistrato, opportunamento curvata e lavorata, per la realizzazione di letti di tipo anatomico.
FI844769A7 (fi) Vasikan rehu ja siinä käytettävä lisäaine.
ES285527U (es) Estante perfeccionado
ATE28269T1 (de) Sessel- und/oder bett-anordnung.
IT8522726A0 (it) Composto ad attivita' antivirale e composizioni che lo contengono.
IT8460508V0 (it) Poltroncina metallica perfezionata.
DK606483A (da) Synergistisk kombination med cytostatisk virkning
ATE60798T1 (de) Menschlicher tumornekrosisfaktor.
ZA872562B (en) Combination therapy using interleukin-2 and/or interferon-beta and tumor necrosis factor
IL105271A0 (en) Compositions comprising tumor necrosis factor and an interferon

Legal Events

Date Code Title Description
KB Patent renewed
RH1 Patent not in force